Last reviewed · How we verify
BEAC
At a glance
| Generic name | BEAC |
|---|---|
| Sponsor | Ruijin Hospital |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparison of ASCT and Conventional Chemotherapy in High Risk Waldenström Macroglobulinemia (PHASE4)
- Efficacy and Safety of Chi-BEAC Combining With Auto-HSCT to Treat Aggressive Lymphoma Subjects (PHASE2)
- Efficacy and Safety of Cladribine Combined With BEAC Pretreatment Regimen in the Treatment of Peripheral T-cell Lymphoma: a Multicenter Clinical Study (PHASE3)
- Multi-day Doses in Prevention of Nausea and Emesis (PHASE2)
- Effect of Short Peripheral Electrical Stimulation (PES) on Blood Glucose (NA)
- Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BEAC CI brief — competitive landscape report
- BEAC updates RSS · CI watch RSS
- Ruijin Hospital portfolio CI